Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)J Immunother Cancer 2021 Oct 01;9(10)xx, PKH Lau, B Feran, L Smith, A Lasocki, R Molania, K Smith, A Weppler, C Angel, D Kee, P Bhave, B Lee, RJ Young, A Iravani, HA Yeang, IA Vergara, D Kok, K Drummond, PJ Neeson, KE Sheppard, T Papenfuss, BJ Solomon, S Sandhu, GA McArthur
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.